These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 30573964)
1. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. Skelley JW; Carter BS; Roberts MZ Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964 [TBL] [Abstract][Full Text] [Related]
2. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Carbone S; Dixon DL Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195 [TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478 [TBL] [Abstract][Full Text] [Related]
11. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V; J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987 [TBL] [Abstract][Full Text] [Related]
12. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120 [TBL] [Abstract][Full Text] [Related]
13. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Whalen K; Miller S; Onge ES Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804 [TBL] [Abstract][Full Text] [Related]
14. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D; Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497 [TBL] [Abstract][Full Text] [Related]
15. Can we go beyond surrogates? Drexler A J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750 [TBL] [Abstract][Full Text] [Related]
16. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883 [TBL] [Abstract][Full Text] [Related]
19. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240 [No Abstract] [Full Text] [Related]
20. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]